(Q47376469)

English

Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study

scientific article published in September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

7

object named as

Jos H Beijnen

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Alwin D R Huitema

3

object named as

Alwin D R Huitema

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Jan H M Schellens

6

object named as

Jan H M Schellens

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

author name string

Markus Joerger

1

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Stefanie Kraff

2

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Gary Feiss

4

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Berta Moritz

5

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Ulrich Jaehde

8

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

publication date

1 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

51

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

9

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

607-617

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

https://scigraph.springernature.com/pub.10.1007/bf03261934

0 references

Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1007%2FBF03261934

21 January 2018

Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism-based pharmacokinetic model for paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal schedule of paclitaxel: weekly is better

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic models for the saturable distribution of paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/22804749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF03261934

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22804749

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47376469&oldid=2154277644"